



Christoph Kaiser

Contact

Christoph Kaiser

Publications (29)

Mahfoud F, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Kaiser C, Cattaneo M, Scheller B, Jeger R. Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. *Clin Res Cardiol* 2022; 111:806-815.

Mangner N, Farah A, Ohlow M, Möbius-Winkler S, Weilenmann D, Wöhrle J, Linke A, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Scheller B, Jeger R, BASKET-SMALL 2 Investigators. Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. *Circ Cardiovasc Interv* 2022; 15:e011325.

Imori Y, Kato K, Cammann V, Szawan K, Wischnewsky M, Dreiding S, Würdinger M, Schönberger M, Petkova V, Niederseer D, Levinson R, Di Vece D, Gili S, Seifert B, Wakita M, Suzuki N, Citro R, Bossone E, Heiner S, Knorr M, Jansen T, Münzel T, D'Ascenzo F, Franke J, Sorici-Barb I, Katus H, Sarcon A, Shinbane J, Napp L, Bauersachs J, Jaguszewski M, Shiomura R, Nakamura S, Takano H, Noutsias M, Burgdorf C, Ishibashi I, Himi T, Koenig W, Schunkert H, Thiele H, Kherad B, Tschope C, Pieske B, Rajan L, Michels G, Pfister R, Mizuno S, Cuneo A, Jacobshagen C, Hasenfuß G, Karakas M, Mochizuki H, Pott A, Rottbauer W, Said S, Braun-Dullaeus R, Banning A, Isogai T, Kimura A, Cuculi F, Kobza R, Fischer T, Vasankari T, Airaksinen K, Tomita Y, Budnik M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Murakami T, Ikari Y, Empen K, Beug D, Felix S, Delmas C, Lairez O, Yamaguchi T, El-Battrawy I, Akin I, Borggrefe M, Horowitz J, Kozel M, Tousek P, Widimsky P, Gilyarova E, Shilova A, Gilyarov M, Neuhaus M, Meyer P, Arroja J, Chan C, Bridgman P, Galuszka J, Poglajen G, Carrilho-Ferreira P, Pinto F, Hauck C, Maier L, Liu K, di Mario C, Paolini C, Bilato C, Bianco M, Jörg L, Rickli H, Winchester D, Ukena C, Böhm M, Bax J, Prasad A, Rihal C, Saito S, Kobayashi Y, Lüscher T, Ruschitzka F, Shimizu W, Ghadri J, Templin C. Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. *Clin Res Cardiol* 2021; 111:186-196.

Iglesias J, Windecker S, Valgimigli M, Heg D, Kaiser C, Weilenmann D, Kurz D, Roffi M, Losdat S, Muller O, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. *Int J Cardiol* 2021; 334:37-41.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwe S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. *Cardiovasc Revasc Med* 2021; 34:3-10.

Wöhrle J, Jeger R, Kaiser C, Gilgen N, Cattaneo M, Rickenbacher P, Leibundgut G, Stachel G, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, Seeger J, Scheller B, BASKET-SMALL 2 Investigators. Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial. *JACC Cardiovasc Interv* 2021; 14:1789-1798.

Jeger R, Scheller B, Kaiser C, Gilgen N, Cattaneo M, Osswald S, Rickenbacher P, Leibundgut G, Markovic S, Stachel G, Wöhrle J, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, BASKET-SMALL 2 Investigators. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. *Lancet* 2020; 396:1504-1510.

Shilova A, Shoji T, Ishibashi I, Takahara M, Himi T, Din J, Al-Shammari A, Prasad A, Rihal C, Liu K, Schulze P, Bianco M, Kobayashi Y, Bilato C, Paolini C, Gilyarov M, El-Battrawy I, Akin I, Poledniková K, Tousek P, Winchester D, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Jörg L, Rickli H, Bauersachs J, Katus H, Horowitz J, di Mario C, Münzel T, Crea F, Bax J, Lüscher T, Ruschitzka F, Ghadri J, Opolski G, Thiele H, Borggreffe M, Schunkert H, Pestana G, Nguyen T, Böhm M, Maier L, Pinto F, Widimsky P, Felix S, Braun-Dullaeus R, Rottbauer W, Hasenfuß G, Pieske B, Templin C, Gilyarova E, Cammann V, Jaguszewski M, Noutsias M, Knorr M, Heiner S, D'Ascenzo F, Dichtl W, Burgdorf C, Kherad B, Tschope C, Sarcon A, Shinbane J, Meder B, Franke J, Neuhaus M, Szawan K, Stähli B, Kato K, Budnik M, Wischnewsky M, Dreiding S, Levinson R, Di Vece D, Gili S, Citro R, Bossone E, Rajan L, Michels G, Airaksinen K, Napp L, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Vasankari T, Fischer T, Kobza R, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Roffi M, Banning A, Wolfrum M, Cuculi F, Lairez O. Age-Related Variations in Takotsubo Syndrome. *J Am Coll Cardiol* 2020; 75:1869-1877.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.

Iglesias J, Windecker S, Jüni P, Zwahlen M, Oduyayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet* 2019; 394:1243-1253.

Lairez O, Hauck C, Paolini C, Bilato C, Prasad A, Rihal C, Liu K, Schulze P, Bianco M, Jörg L, Rickli H, Carrilho-Ferreira P, Poglajen G, El-Battrawy I, Akin I, Gilyarova E, Shilova A, Gilyarov M, Kozel M, Tousek P, Winchester D, Galuszka J, Ukena C, Nguyen T, Kobayashi Y, Böhm M, Bauersachs J, Katus H, Horowitz J, di Mario C, Münzel T, Crea F, Bax J, Lüscher T, Ruschitzka F, Ghadri J, Thiele H, Schunkert H, Maier L, Pinto F, Widimsky P, Borggreffe M, Felix S, Opolski G, Braun-Dullaeus R, Rottbauer W, Hasenfuß G, Pieske B, Templin C, Delmas C, Wischnewsky M, Sorici-Barb I, Jaguszewski M, Noutsias M, Knorr M, Heiner S, Burgdorf C, Kherad B, Tschope C, Sarcon A, Shinbane J, Franke J, Neuhaus M, Candreva A, Bacchi B, Cammann V, Kato K, Szawan K, Gili S, D'Ascenzo F, Dichtl W, Citro R, Bossone E, Rajan L, Michels G, Pfister R, Airaksinen K, Napp L, Budnik M, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Vasankari T, Fischer T, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Arroja J, Banning A, Cuculi F, Kobza R, Beug D. Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. *Eur J Heart Fail* 2019; 21:1469-1472.

Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. *Circ Cardiovasc Interv* 2019; 12:e008024.

Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuillomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. *PLoS one* 2019; 14:e0210821.

Jeger R, Stephan F, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B, Linke A, Mahfoud F, Schreiber M, Farah A, Ohlow M, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. *Lancet* 2018; 392:849-856.

Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet* 2018; 392:737-746.

Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuillomenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. *EuroIntervention* 2018; 14:692-699.

Gilgen N, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan F, Coslovsky M, Jeger R, Krackhardt F, Zweiker R, Farah A, Scheller B, Ohlow M, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, BASKET-SMALL 2 Investigators. Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. *Clin Cardiol* 2018; 41:569-575.

Rigamonti F, Kaiser C, Rickli H, Corti R, Röthlisberger C, Wenaweser P, Weilenmann D, Cook S, Maeder M, Fahrni G, Roffi M. Switzerland: coronary and structural heart interventions from 2010 to 2015. *EuroIntervention* 2017; 13:Z75-Z79.

Pilgrim T, Jüni P, Wenaweser P, Blöchliger S, Nietlisbach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuillomenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. *EuroIntervention* 2015; 11

Vassalli G, Pedrazzini G, Pfisterer M, Kaiser C, Moccetti T, Bonetti P, Bertel O, Hornig B, Rickli H, Eberli F, Erne P, Galatius S, De Servi S, Klersy C, BASKET-PROVE Investigators. Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial. *Am Heart J* 2015; 173:1-7.

Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuillomenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. *Circ Cardiovasc Interv* 2015; 8

Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROSpective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. *Circulation* 2014; 131:74-81.

Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuillomenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. *Lancet* 2014; 384:2111-22.

Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuillomenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. *Am Heart J* 2014; 168:256-61.

Jensen M, Galatius S, Pfisterer M, Erne P, De Servi S, Bertel O, Fahrni G, Zurek M, Rickli H, Soerensen R, Pedersen S, Jensen J, Iversen A, Wanitschek M, Alber H, Sandsten K, Kaiser C, BASKET-PROVE Investigators. Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial. *Int J Cardiol* 2013; 168:3802-6.

Jeger R, Gilgen N, Vuilliomonet A, Jensen J, Rickli H, Pedrazzini G, Naber C, Galatius S, Eberli F, Alber H, Pfisterer M, Kaiser C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. *Am Heart J* 2012; 163:136-41.e1.

Kaiser C, Pfisterer M, Ricard I, Brunner-La Rocca H, De Servi S, Bonetti P, Bertel O, Hornig B, Pedrazzini G, Rickli H, Alber H, Eberli F, Erne P, Galatius S, BASKET-PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries. *N Engl J Med* 2010; 363:2310-9.

Pfisterer M, Kaiser C, De Servi S, Rickli H, Pedrazzini G, Pachinger O, Klowski W, Hornig B, Galatius S, Erne P, Eberli F, Brunner-La Rocca H, Bonetti P, Bertel O, BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. *American heart journal* 2008; 155:609-14.

Bernheim A, Pfisterer M, Buser P, Linka A, Kaiser C, Kiencke S, Eckstein J, Brunner-La Rocca H, Schaer B, Burger P, Sticherling C, Ammann P, Osswald S. Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacing. *Journal of the American College of Cardiology* 2005; 45:1482-7.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch